A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion
This study is testing a new medication called YH42946 to see how safe it is and how well it works against certain types of advanced solid tumors and lung cancer. Researchers want to help patients whose cancer has specific genetic changes known as HER2 aberrations or EGFR exon 20 insertions.
You may be able to join if you have advanced solid tumors or non-small cell lung cancer with specific genetic markers, and standard treatments have not worked well or are not an option. Participants also need to be well enough to carry out daily activities and meet certain heart health requirements.
Participants will receive the study medication, YH42946, while doctors closely monitor their health, side effects, and how the medicine affects their tumor. You will also need to provide a tumor tissue sample for genetic testing and attend regular check-ups.
This study is currently recruiting participants at locations in Virginia, United States, and in Gyeonggi-do, South Korea.
- 1Testing a new medicine called YH42946 for advanced solid tumors and lung cancer.
- 2Open to patients with specific genetic mutations who need new treatment options.
- 3Currently recruiting participants in the United States and South Korea.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.